Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP776944.RAbE5Sv84lZedP6RIvh16LjA2tHikheVjLl3FvkCyUC8o130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP776944.RAbE5Sv84lZedP6RIvh16LjA2tHikheVjLl3FvkCyUC8o130_provenance.
• NP763031.RAd9ITBL3mYwCnMfwdzYI9dkvy22WYZrDIvl1Ccbvjp34130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP763031.RAd9ITBL3mYwCnMfwdzYI9dkvy22WYZrDIvl1Ccbvjp34130_provenance.
• NP938399.RAi-L4IR3ST1NbWRJyYfCQUS1ckdgnMUMuxWlxfHSN8jQ130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP938399.RAi-L4IR3ST1NbWRJyYfCQUS1ckdgnMUMuxWlxfHSN8jQ130_provenance.
• NP441083.RAMKm3LgAb-2iFzxy2wvKLPcDzTIbsURvnIPwkkAIQ0WA130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP441083.RAMKm3LgAb-2iFzxy2wvKLPcDzTIbsURvnIPwkkAIQ0WA130_provenance.
• NP158467.RA0WSIN2qyy6fzRcujX4FHUb9sFBdLPcM4aYOw1TqLTwE130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP158467.RA0WSIN2qyy6fzRcujX4FHUb9sFBdLPcM4aYOw1TqLTwE130_provenance.
• NP675962.RAt9lFP5l75DO4yRJ_S6jlBjfEkO33KN044FVUWDo1zCM130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675962.RAt9lFP5l75DO4yRJ_S6jlBjfEkO33KN044FVUWDo1zCM130_provenance.
• NP320448.RANQHNpxzNrhBNp0rBAp1BzHY7oSuiZ4YNMN7NyNOV8Wo130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP320448.RANQHNpxzNrhBNp0rBAp1BzHY7oSuiZ4YNMN7NyNOV8Wo130_provenance.
• NP341495.RACpcCdZn7ssuMA3EPEeSsMyKNvhDDdtS0zL62846CW5w130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341495.RACpcCdZn7ssuMA3EPEeSsMyKNvhDDdtS0zL62846CW5w130_provenance.
• NP341499.RADoYxj-iKpHWc2bqEmt3fU7pKSeKGVxtI77Q7ODaS0-E130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341499.RADoYxj-iKpHWc2bqEmt3fU7pKSeKGVxtI77Q7ODaS0-E130_provenance.
• NP487181.RAEFhHSrCh7zBt0rywcZLPixFoFPIDI9EcQFlWxsU1IvE130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP487181.RAEFhHSrCh7zBt0rywcZLPixFoFPIDI9EcQFlWxsU1IvE130_provenance.
• NP737160.RAPRINPPB7WGf7n98p_zM6ZX9CRi09nraBA_oo7QA652I130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP737160.RAPRINPPB7WGf7n98p_zM6ZX9CRi09nraBA_oo7QA652I130_provenance.
• NP842014.RA1OrC-iL8Wb6T2se-fd80mSWh3gFxVv9q8aNrh84z_Hw130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP842014.RA1OrC-iL8Wb6T2se-fd80mSWh3gFxVv9q8aNrh84z_Hw130_provenance.
• NP341611.RAxbtR_PpfcjFVsBIvynHefpDQQfXZLwRm8F0Xk6-LqUI130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341611.RAxbtR_PpfcjFVsBIvynHefpDQQfXZLwRm8F0Xk6-LqUI130_provenance.
• NP341704.RA8v6AkW3z_y86xaECVXsQWwBvC33N0s5rmoBAQWasP5c130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341704.RA8v6AkW3z_y86xaECVXsQWwBvC33N0s5rmoBAQWasP5c130_provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP557492.RA-StNniHN0GoP2mtF11vT_9XYbB2mVQpW3_IkmEcLrwM130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557492.RA-StNniHN0GoP2mtF11vT_9XYbB2mVQpW3_IkmEcLrwM130_provenance.
• NP557495.RA9x_8rhtwbW1W9R5b-A5L66iNE3VMu_bI0G6lNviF7T4130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557495.RA9x_8rhtwbW1W9R5b-A5L66iNE3VMu_bI0G6lNviF7T4130_provenance.
• NP342225.RAGkBjnWtNtgDvGlia9qkbiYOzg3udVGI0dJ8ZGEKK6hk130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP342225.RAGkBjnWtNtgDvGlia9qkbiYOzg3udVGI0dJ8ZGEKK6hk130_provenance.
• NP557490.RAeTC1d6C-PU1UMNIqF_WMdL_5LE9F-T_ybq4g5t_cIOk130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557490.RAeTC1d6C-PU1UMNIqF_WMdL_5LE9F-T_ybq4g5t_cIOk130_provenance.
• NP342215.RAp1EM90qNpm0UfnhIEDFxdAWUNH2qSuvQg1U0wDgQj7I130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP342215.RAp1EM90qNpm0UfnhIEDFxdAWUNH2qSuvQg1U0wDgQj7I130_provenance.
• NP557491.RArsCCYQ5tn66kLo1EAAzX1AEcVaTVokYJM9uH4voALsE130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557491.RArsCCYQ5tn66kLo1EAAzX1AEcVaTVokYJM9uH4voALsE130_provenance.
• NP557493.RAu4ekFS5cZawyXi5OWwWRnILAa-dStIbhgvuGg6kfWzs130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557493.RAu4ekFS5cZawyXi5OWwWRnILAa-dStIbhgvuGg6kfWzs130_provenance.
• NP557494.RApawXncULzkl9VVhUeuvh3qAA6nFONSoClAUgn0HKbjs130_assertion description "[We evaluated whether cytochrome P450 (CYP) poor metabolizer polymorphisms of CYP2D6 and CYP2C19 are relevant for the outcome (measured by length of hospitalization) during treatment with psychotropic medications in patients with depression or schizophrenia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP557494.RApawXncULzkl9VVhUeuvh3qAA6nFONSoClAUgn0HKbjs130_provenance.